selumetinib — CareFirst (Caremark)
neurofibromatosis type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN)
Initial criteria
- Member has symptomatic, inoperable plexiform neurofibromas (PN)
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months